Clinical trials: Sunitinib, completed
Pancreatic Neuroendocrine Tumors
Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
The purpose of the study is to evaluate the effect of Sunitinib on the clinical benefit response rate.
- Trial name
- NCT01121562
- Testing
- Sunitinib
- Where
- 4 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Breast Neoplasms
Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer
This study is to evaluate the safety of SU011248 (Sunitinib/Sutent) in combination with docetaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease…
- Trial name
- NCT00291577
- Testing
- Sunitinib (Sutent), Taxotere
- Where
- 3 sites in Belgium, Italy and 1 more
- Volunteers
- 22 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00716625
- Testing
- sunitinib malate
- Volunteers
- 1,674 people
- Sponsor
- Pfizer
Solid Tumors
A Phase I Trial of Bortezomib and Sunitinib
The purpose of this study is to test the effect of the combination of sunitinib and bortezomib. We will see what effects it has on your cancer and find the highest dose of each agent that can be given without causing severe side…
- Trial name
- NCT00720148
- Testing
- Sunitinib and Bortezomib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
This phase II trial is studying how well sunitinib works in treating patients with metastatic pancreatic cancer that progressed after first-line therapy with gemcitabine.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00397787
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)